Elicera recruits Ingvar Karlsson as CFO.
Ingvar has extensive experience from CFO positions in both public and private companies, including listed cell therapy company Idogen.
For more information, please read the article in the link below.
Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.
"Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy for glioblastoma, an aggressive form of brain cancer that is often difficult to treat.
Their project is now entering the final preclinical stage of development, according to the university. The goal is to start clinical studies within four years."
Financial Times writes an article about Elicera Therapeutics and the donation of shares to the VictoryNET-foundation.
The successful collaborative project between Magnus Essand and Di Yu on one hand and the Drug Development and Discovery Platform (DDD) at SciLifeLab on the other reached the Exit Milestone after two and a half years. The project led to the development of a chimeric antigen receptor (CAR) targeting IL13R2a (ELC-401).
The DDD Platform is a National Resource that helps researcher take academic findings into commercial product development.
Di Yu is awarded the prestigious Göran Gustavsson Prize by the Royal Swedish Academy of Sciences for his research in CAR T-cells and oncolytic viruses.
Professor Magnus Essand is awarded SEK 6 million in funding from the Sjöberg Foundation for the development of ELC-401.
Professor Magnus Essand is granted SEK 13.5 million in funding by the Swedish Cancer Society for the development of ELC-301 and ELC-401.
Uppsala University provides a status update in short video clip of the ongoing phase I/II-study in NET.
The Medical Journal (Läkartidningen) writes about a clinical study with an oncolytic virus that was financed with a total of SEK 14 million via crowdfunding (ELC-100)
Swedish Public Radio interviews Professor Magnus Essand on the occasion of securing crowdfunding to initiate a clinical study with the oncolytic virus AdVince (ELC-100).
Immunicum AB acquires a patent from VirEx AB (now Elicera Therapeutics) and simultaneously gives an exclusive global license for the development of an oncolytic virus (ELC-100) for the treatment of neuroendocrine tumors.
Planning of a clinical study with oncolytic virus (ELC-100), commences after successful crowdfunding. Background: Author and freelance journalist Alexander Masters from England contacts Professor Magnus Essand to explore the possibilities of using the oncolytic virus to treat a friend and colleague affected by NET. Professor Essand informs that funding to start a clinical trial is lacking which Alexander Masters subsequently writes about in the British newspaper "The Telegraph" where he also suggests that anyone who donates a million British pounds should have the virus named after him. The article gets wide spread attention and a crowdfunding campaign, iCancer, is initiated by Alexander Masters, Dominic Nutt and Liz Scarff to get the funds needed for a clinical trial in NET. As a result, thousands of people from around the world together donate a substantial sum for the cause of which the majority by oil tycoon Vince Hamilton, himself affected by NET. The oncolytic virus is named AdVince in his honor.